This was a secondary analysis examining the occurrence of renal abnormalities ( RAs ) and renal and metabolic serious non-AIDS-defining events ( SNADEs ) through study follow-up between participants randomized to zidovudine ( ZDV ) / lamivudine / efavirenz and TDF/emtricitabine/efavirenz treatment arms within A5175/PEARLS trial .